Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T16:43:23.317Z.
Calculation as of: 2026-10-06T16:43:23.317Z.
Quote observation: 2026-10-06T16:38:55.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1439c3a9e54fb1f97ae208c5489c534aa692153c8f3b45d8dac24981f451ae3
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LeonaBio, Inc. (LONA) | $22.28M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.31M | N/A | N/A | N/A | N/A |
| Modular Medical, Inc. (MODD)vs › | $21.48M | N/A | N/A | N/A | N/A |
| Rein Therapeutics Inc. (RNTX)vs › | $22.97M | N/A | N/A | N/A | N/A |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.80M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.38M | N/A | 2502.34 | 2502.34 | 2502.34 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.51M | N/A | N/A | N/A | N/A |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.70M | N/A | 2021.12 | 2021.12 | 2021.12 |
| Actuate Therapeutics Inc (ACTU)vs › | $19.72M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $18.95M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$5.65
Forward EPS (Est.)
$-2.83
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
